[Market Focus] AJU IB Investment Soars 30% on Hopes for Investment Returns
The stock price of AJU IB Investment, a venture capital (VC) firm, surged on heightened expectations for global bio investment returns.
As of 10:03 a.m. on February 27, AJU IB Investment was trading at 5,810 won, up 1,340 won (29.98%) from the previous day.
According to foreign media reports the previous day, global pharmaceutical company Gilead has agreed to acquire Axcella Therapeutics, a bio company invested in by Solasta Ventures, for 7.8 billion dollars (about 10 trillion won). Axcella Therapeutics is a company invested in by Solasta Ventures, the U.S. subsidiary of AJU IB Investment.
Hot Picks Today
!["Big Gains for Holders... Up 566% and Still More to Go" Target Price Raised, But Here’s Why Caution Remains [Weekend Money]](https://cwcontent.asiae.co.kr/asiaresize/93/2025090513580721483_1757048288.jpg)
"Big Gains for Holders... Up 566% and Still More to Go" Target Price Raised, But Here’s Why Caution Remains [Weekend Money]
- "Data Centers Ignite ESS Order Rally Expectations for This Company [Weekend Money]"
- "Achieving 1 Billion Won Through Stocks" Office Worker Remains Optimistic Despite Mandatory Paid Leave and Halved Salary
- Every Show Sold Out in North America... How Much Did BTS Earn from the Tour?
- "Best Homeroom Teacher"... Hong Kong Education Sector in Shock Over Spread of "Princess Carry" Photos
AJU IB Investment has been divesting from Axcella Therapeutics since its listing on the NASDAQ in 2023 and into last year. It is known that the company still holds a significant portion of shares. AJU IB Investment expects an investment multiple of up to 9 times its original principal.
![[Market Focus] AJU IB Investment Soars 30% on Hopes for Investment Returns](http://www.asiae.co.kr/news/img_view.htm?img=2026022709360655459_1772152566.jpg)
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
